Home
>
US Stocks
>
Landos Biopharma Inc
Landos Biopharma Inc
LABP

Landos Biopharma Inc

$14.958.02%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
14.94
Today Low/High
14.84 / 14.97
52 Week Low/High
$8.82 / $16.99
Market Cap
$527.55M

Company Details

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma’s core expertise is in the development of therapeutic candidates targeting novel pathways at the interface of immunity and metabolism. Lead asset BT-11 is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes.
Organisation
Landos Biopharma Inc
Employees
33

Discover more

Frequently Asked Questions

What is Landos Biopharma Inc share price today

Can Indians buy Landos Biopharma Inc shares?

How can I buy Landos Biopharma Inc shares from India?

Can Fractional shares of Landos Biopharma Inc be purchased?

What are the documents required to start investing in Landos Biopharma Inc stocks?

We are a SEBI registered investement advisor